Research

lf0 Research Notes

Get future lf0 equity research notes by email.

Weekly stock analysis, SEC filing-change summaries, and quant strategy notes from lf0.

Subscribe to lf0 Research Notes

Equity Research
RELY
Remitly Global Stock Analysis: Buy or Sell? Valuation, Growth, Margins & Cash Flow
Aug 11, 2026
Remitly Global (RELY) is rated Hold as solid revenue growth is offset by a valuation that already discounts much of the progress. Cash and low debt support the balance sheet, but insider selling and only gradual earnings conversion keep the setup mixed.
Read note
Equity Research
CLOV
Clover Health Stock Analysis: Buy or Sell? Valuation & Margins, Cash Flow
Aug 10, 2026
Clover Health Investments Corp. (CLOV) is rated Hold after its first profitable quarter, but trailing margins and free cash flow still lag. The business needs sustained revenue and EBITDA improvement before the new inflection looks durable.
Read note
SEC What Changed
SEC
SEC What Changed: 10-K Filing Snapshot for 10 August 2026
Aug 10, 2026
A ranked snapshot of 10-K language changes for companies that filed annual reports on 10 August 2026.
Read note
Equity Research
WGS
GeneDx Stock Analysis: Buy or Sell? Valuation, Cash Flow & Margins
Aug 9, 2026
GeneDx Holdings Corp. (WGS) is rated Sell as the market prices in a clean earnings recovery that cash flow and margin trends do not yet support. Revenue growth is improving, but positive free cash flow remains elusive and reimbursement pressure could delay a rerating.
Read note
Equity Research
HST
Host Hotels & Resorts Stock Analysis: Buy or Sell? Valuation, FCF & Leverage
Aug 9, 2026
Host Hotels & Resorts (HST) is rated Hold as its cash-flow cushion and 10.5% FCF yield help support the equity. However, the stock already prices in a fair recovery, while leverage and hotel margin improvement remain the key debate.
Read note
Equity Research
EPAM
EPAM Systems Stock Analysis: Buy or Sell? AI Demand, Growth & Margins
Aug 8, 2026
EPAM Systems (EPAM) is rated Hold, supported by a strong cash profile and a net cash balance sheet. Modest growth and geopolitical delivery risk keep the multiple from expanding despite a 12.9% FCF yield.
Read note
SEC What Changed
CLX, CMPR, LRCX, NWSA, RSKIA
Clorox (CLX) 10-K: MD&A Changes Lead 7 August 2026 Filing Roundup
Aug 7, 2026
Clorox (CLX)’s MD&A section changed the most among 5 companies that filed 10-Ks on 7 August 2026, each compared against its prior-year filing.
Read note
Equity Research
APP
AppLovin Stock Analysis: Buy or Sell? Valuation & Privacy Risk
Aug 6, 2026
AppLovin (APP) earns a Hold rating as its ad platform quality and cash generation are strong, but the valuation already prices in a long growth runway. The main tension is whether revenue growth can stay elevated while privacy changes and platform dependence remain manageable.
Read note
SEC What Changed
CACI, CVSA, FOXA, KLAC, OTEX, PTON
Fox (FOXA) 10-K: Business Changes Lead 6 August 2026 Filing Roundup
Aug 6, 2026
Fox (FOXA)’s Business section changed the most among 6 companies that filed 10-Ks on 6 August 2026, each compared against its prior-year filing.
Read note
Equity Research
USAC
USA Compression Partners Stock Analysis: Buy or Sell? Leverage, Distribution Risk & Cash Flow
Aug 5, 2026
USA Compression Partners, LP (USAC) is rated Hold as its fixed-fee compression franchise supports steadier cash flow, but leverage and distribution coverage remain the key constraints. The J W Power deal may lift capacity, yet USAC still needs debt reduction before the payout looks meaningfully safer.
Read note

Get future lf0 research notes by email.

Equity research, SEC filing-change summaries, and quant research — delivered when published. Free, no noise.

Subscribe to lf0 Research Notes

No spam. Unsubscribe anytime.